Varun Shukla Writer-Editorial Content
Writer-Editorial Content
Alembic, Amneal, and Astral Pharmaceutical were among the leading recruiters.
The National Institute of Pharmaceutical Education and Research, Ahmedabad has released the placement report for the class of 2022-24. The program involved 164 students, 28 of whom chose to further their education. 136 students applied for placement, and 90.4% were successfully placed.
| Direct Link: NIPER Placement Report AY 2024 |
NIPER Placement Statistics 2024
The following table contains the placement statistics for the NIPER Placement Batch of 2024:
| Particulars | Details |
|---|---|
| Total no of students | 164 |
| Students opted for Higher studies | 28 |
| Student opted for Placement | 136 |
| Students placed | 123 |
| % of Placement | 90.4% |
NIPER Placement 2024 Top Recruiters
The list of recruiters who expressed the highest interest in the National Institute of Pharmaceutical Education and Research Placement program is shown below:
- Alembic
- Amneal
- Astral Pharmaceutical
- Aten Porus
- Biocon
- Cadila Pharmaceuticals
The placement cell of the National Institute of Pharmaceutical Education and Research prepares students to be technically sound as well as proficient in analysis and problem solving.
Read More:
- NIPER Placement 2024-Check Packages and Recruiters List Here!
- NIPER, Ahmedabad - Program & Fees Details
Subscribe to Collegedunia to get the latest news and updates –
.png?h=127&w=254&mode=stretch)
.png?h=127&w=254&mode=stretch)
-min.png?h=127&w=254&mode=stretch)
-min%20(1).png?h=127&w=254&mode=stretch)
-min.png?h=127&w=254&mode=stretch)
%20(19)-min.png?h=40&w=40&mode=stretch){kind=small}
.png?h=40&w=40&mode=stretch){kind=small}
%20(24)-min.png?h=40&w=40&mode=stretch){kind=small}
%20(23)-min.png?h=40&w=40&mode=stretch){kind=small}
%20(16)-min.png?h=40&w=40&mode=stretch){kind=small}
%20(18)-min.png?h=40&w=40&mode=stretch){kind=small}
.jpeg?h=40&w=40&mode=stretch){kind=small}
.jpeg?h=40&w=40&mode=stretch){kind=small}
.jpeg?h=40&w=40&mode=stretch){kind=small}
Comments